Astellas Thins Pipeline, Halts AT132
April 27, 2026
Astellas halts AT132 gene therapy for myotubular myotrophy ($103M write-down), swaps to ASP2957 and drops two Phase 1 candidates.
Astellas Licenses Dyno Capsid for Muscle Gene Therapy
April 8, 2026
Astellas and Dyno Therapeutics agreed a $15M+ deal for an AI-designed AAV capsid optimised for muscle-disorder gene therapy delivery, extending Dyno's partnering track record.